Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3(+) tumour-infiltrating lymphocytes (TIL) from patients with ovarian an...

Por Melichar, B, Nash, M A, Lenzi, R, Platsoucas, C D, Freedman, R S
Publicado em 2000

P-153 Regorafenib in the real-life clinical practice: data from the czech registry

Por Buchler, T., Bortlicek, Z., Hejduk, K., Melichar, B., Pokorna, P., Linke, Z., Petruželka, L., Finek, J., Prausova, J., Kubáčková, K.
Publicado no Ann Oncol (2016)

Role of CCND1 and C-MYC oncogenes in metastatic breast cancer patients treated by herceptin

Por Trojanec, R, Koudelakova, V, Bouchalova, K, Radova, L, Ondryasova, H, Krejci, E, Megova, M, Cizkova, M, Mlcochova, S, Melichar, B, Hajduch, M
Publicado em 2011

BCL2 is a predictive marker of adjuvant CMF regimen in triple-negative breast cancer patients

Por Bouchalova, K, Cizkova, M, Trojanec, R, Koudelakova, V, Radova, L, Furstova, J, Melichar, B, Cwiertka, K, Kharaishvili, G, Kolar, Z, Hajduch, M
Publicado em 2011

P-005 Prognostic significance of the frequency of primary cilia in cells of small bowel and colorectal adenocarcinoma

Por Kupec, M., Dvorak, J., Hadzi Nikolov, D., Dusek, L., Filipova, A., Richter, I., Buka, D., Ryska, A., Mokry, J., Filip, S., Melichar, B., Buchler, T., Abrahamova, J.
Publicado no Ann Oncol (2016)

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer

Por Adiwijaya, BS, Kim, J, Lang, I, Csõszi, T, Cubillo, A, Chen, J‐S, Wong, M, Park, JO, Kim, JS, Rau, KM, Melichar, B, Gallego, JB, Fitzgerald, J, Belanger, B, Molnar, I, Ma, WW
Publicado no Clin Pharmacol Ther (2017)

Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial

Por Melichar, B, Casado, E, Bridgewater, J, Bennouna, J, Campone, M, Vitek, P, Delord, J-P, Cerman, J, Salazar, R, Dvorak, J, Sguotti, C, Urban, P, Viraswami-Appanna, K, Tan, E, Tabernero, J
Publicado em 2011

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer

Por Deplanque, G., Demarchi, M., Hebbar, M., Flynn, P., Melichar, B., Atkins, J., Nowara, E., Moyé, L., Piquemal, D., Ritter, D., Dubreuil, P., Mansfield, C. D., Acin, Y., Moussy, A., Hermine, O., Hammel, P.
Publicado no Ann Oncol (2015)

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

Por Brodowicz, T, Lang, I, Kahan, Z, Greil, R, Beslija, S, Stemmer, S M, Kaufman, B, Petruzelka, L, Eniu, A, Anghel, R, Koynov, K, Vrbanec, D, Pienkowski, T, Melichar, B, Spanik, S, Ahlers, S, Messinger, D, Inbar, M J, Zielinski, C
Publicado no Br J Cancer (2014)

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the panc...

Por Fuchs, C. S., Azevedo, S., Okusaka, T., Van Laethem, J.-L., Lipton, L. R., Riess, H., Szczylik, C., Moore, M. J., Peeters, M., Bodoky, G., Ikeda, M., Melichar, B., Nemecek, R., Ohkawa, S., Świeboda-Sadlej, A., Tjulandin, S. A., Van Cutsem, E., Loberg, R., Haddad, V., Gansert, J. L., Bach, B. A., Carrato, A.
Publicado no Ann Oncol (2015)